AzTrials
AzTrials

Familial Mediterranean FeverNCT05596643

Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever

An observational study of Familial Mediterranean Fever and Autonomic Dysfunction, run by Marmara University at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Familial Mediterranean Fever (FMF) is the most common inherited autoinflammatory disease affecting 150,000 patients worldwide. Periodic febrile exacerbations, peritonitis, and pleuritis are characteristic disease features. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
What is being tested?
Composite Autonomic Symptom Score-31, r-r interval variability with normal breathing and r-r interval variability with deep breathing
How many people
60 participants
Where
1 siteTurkey (Türkiye)
Study dates
15 Mar 2022to 31 Oct 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients with FMF Healthy control group

Who may be able to join

  • Familial Mediterranean Fever group;
  • Being between the ages of 18-65
  • Having a definite diagnosis of Familial Mediterranean Fever according to Livneh criteria
  • Healthy control group;
  • Being between the ages of 18-65
  • Absence of any disease diagnosis

Who cannot join

  • Liver or kidney failure
  • Pregnancy
  • Diabetes mellitus
  • Thyroid diseases
  • Those who use neuroprotective or antihypertensive drugs
  • Vitamin B12 deficiency
Show all 14Show fewer
  • Anemia
  • Paraneoplastic neuropathy
  • Alcoholism
  • Cardiac failure
  • Cardiac arrhythmia
  • Acute thrombosis
  • Having a diagnosis of another systemic rheumatic disease
  • Persons who did not give consent to participate in the study

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site, 1 recruiting
  • Marmara University School of Medicine, Pendik Education and Research Hospital, Department of Physical Medicine and Rehabilitation

    Istanbul

    İmran Kalkan, +90 530 340 5594, imrankalkann55@gmail.com

    Mehmet Tuncay Duruöz, Prof

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Familial Mediterranean Fever (FMF) is the most common inherited autoinflammatory disease affecting 150,000 patients worldwide. Periodic febrile exacerbations, peritonitis, and pleuritis are characteristic disease features. Dysregulation of IL-1β secretion has an important role in the pathophysiology of the disease, and IL-1β also serves as a therapeutic target. Chronic inflammation has been associated with early atherosclerotic and cardiovascular disease in various rheumatic diseases. An increased risk for cardiovascular events associated with disease activity has been described in rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. In addition, autonomic nervous system dysfunction may contribute to increased cardiovascular risk in patients with inflammatory disease. For example, decreased heart rate variability is an important feature of cardiac autonomic dysfunction and is an isolated risk factor for cardiovascular events. Autonomic dysfunction studies related to FMF have conflicting results.

The aim of this study was to determine autonomic dysfunction symptoms and objective findings in patients with FMF; Demographic characteristics, disease characteristics, inflammatory burden, fatigue level, sleep quality, presence of fibromyalgia and their relationship with quality of life were evaluated and compared with healthy controls.

Being tested
Composite Autonomic Symptom Score-31, r-r interval variability with normal breathing, r-r interval variability with deep breathing, Valsalva ratio, 30:15 ratio
Keywords
Familial Mediterranean Fever, Autonomic Dysfunction, r-r interval variability, sympathetic skin response
Medical subject headings
Familial Mediterranean Fever, Primary Dysautonomias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Composite Autonomic Symptom Score-31Diagnostic test

    Also called COMPASS-31

    Standardized questionnaire to determine the level of autonomic dysfunction

  • r-r interval variability with normal breathingDiagnostic test

    electrophysiological test to detect parasympathetic dysfunction

  • r-r interval variability with deep breathingDiagnostic test

    electrophysiological test to detect parasympathetic dysfunction

  • Valsalva ratioDiagnostic test

    electrophysiological test to detect parasympathetic dysfunction

  • 30:15 ratioDiagnostic test

    electrophysiological test to detect parasympathetic dysfunction

  • sympathetic skin responseDiagnostic test

    Also called SSR

    electrophysiological test to detect sympathetic dysfunction

  • blood pressure response to standingDiagnostic test

    clinical test to detect sympathetic dysfunction

  • blood pressure response to sustained handgrip testDiagnostic test

    clinical test to detect sympathetic dysfunction

  • Hospital anxiety and depression scaleOther

    Also called HADS

    Standardized questionnaire to investigate the depression and anxiety

  • Fibromyalgia rapid screening toolDiagnostic test

    Also called FIRST

    Standardized questionnaire to determine the presence of fibromyalgia

  • Familial Mediterranean Fever Quality of life scaleOther

    Also called FMFQoL

    Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients

  • Jenkins Sleep Evaluation ScaleOther

    Standardized questionnaire to investigate the sleep quality and disturbance

  • The Fatigue Severity ScaleOther

    Also called FSS

    Standardized questionnaire to investigate the fatigue severity

Study groups in NCT05596643
Study groupRoleWhat they receive
Patients diagnosed with Familial Mediterranean FeverNot described
Receives: Diagnostic Test: Composite Autonomic Symptom Score-31; Diagnostic Test: r-r interval variability with normal breathing; Diagnostic Test: r-r interval variability with deep breathing; Diagnostic Test: Valsalva ratio; Diagnostic Test: 30:15 ratio; Diagnostic Test: sympathetic skin response; Diagnostic Test: blood pressure response to standing; Diagnostic Test: blood pressure response to sustained handgrip test; Other: Hospital anxiety and depression scale; Diagnostic Test: Fibromyalgia rapid screening tool; Other: Familial Mediterranean Fever Quality of life scale; Other: Jenkins Sleep Evaluation Scale; Other: The Fatigue Severity Scale
Healthy ControlsNot described
Receives: Diagnostic Test: Composite Autonomic Symptom Score-31; Diagnostic Test: r-r interval variability with normal breathing; Diagnostic Test: r-r interval variability with deep breathing; Diagnostic Test: Valsalva ratio; Diagnostic Test: 30:15 ratio; Diagnostic Test: sympathetic skin response; Diagnostic Test: blood pressure response to standing; Diagnostic Test: blood pressure response to sustained handgrip test; Other: Hospital anxiety and depression scale; Diagnostic Test: Fibromyalgia rapid screening tool; Other: Jenkins Sleep Evaluation Scale; Other: The Fatigue Severity Scale

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite Autonomic Symptom Score-31

    It is a widely applicable, up-to-date, easy-to-apply and scientifically-based test that evaluates autonomic symptoms and functions by the person himself. It consists of 31 multiple-choice questions in 6 autonomic areas: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder function and pupillomotor areas. A score in the range of 0-100 is obtained as a result of multiplying each area by the weight factor determined by the study. High score indicates presence and severity of autonomic dysfunction.

    Measured: 6 months

  2. r-r interval variability with normal breathing

    The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. The R-R interval variability is calculated automatically by the electromyography device over a 1-minute recording.

    Measured: 6 months

  3. r-r interval variability with deep breathing

    The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. In order to determine the R-R interval variability with deep breathing, the patient is given 6 to 8 deep breaths, consisting of 5 seconds of inspiration followed by 5 seconds of expiration, and the result is automatically calculated by the electromyography device.

    Measured: 6 months

  4. Valsalva ratio

    The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. The test was performed by asking the subject to sit quietly and then blow into a mouthpiece attached to an aneroid pressure gauge at a pressure of 40 mmHg for 15 seconds. The ratio of the longest R-R interval shortly after the manoeuver (within about 20 beats) and the shortest R-R interval during the manoeuver is then measured. The result was expressed as the Valsalva ratio that is taken as the mean ratio from three successive Valsalva manoeuvers.

    Measured: 6 months

  5. 30:15 ratio

    The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist.The R-R interval on the ECG was recorded and used to determine the instantaneous HR at rest and then on the 15th and 30th beats after standing. The HR should normally rise after about 30 seconds as part of the response to return the blood pressure (BP) to normal. After standing up, the 30:15 ratio obtained by dividing the longest R-R distance around the 30th beat by the shortest R-R distance around the 15th beat was calculated automatically by the EMG device.

    Measured: 6 months

  6. sympathetic skin response

    Sweating that occurs in response to many different stimuli, electrolyte in the skin triggers changes in skin conductivity, resulting in instantaneous changes in skin conductivity. Sympathetic skin response evaluates these instantaneous changes in the skin in response to sweating. Sympathetic skin response reflects the function of sympathetic nerve fibers.Active recording electrodes on palm and sole; reference electrodes is placed on the back of the hand and the back of the foot. Responses obtained by applying electrical current over the median nerve trace are evaluated.

    Measured: 6 months

  7. blood pressure response to standing

    Participants were asked to stand up for 3 minutes after a 10-minute resting period in a supine position. The systolic and diastolic BP (SBP and DBP) just before standing, and 3 minutes after active standing were determined, in order to define postural change in BP and to evaluate orthostatic intolerance.

    Measured: 6 months

  8. blood pressure response to sustained handgrip

    Blood pressure measurement is continued at 1-minute intervals while patients perform sustained handgip at 30% of their maximum volitional strength for 5 minutes.The absolute difference between the highest DBP during handgrip and the basal DBP just before the handgrip was noted.

    Measured: 6 months

Secondary outcomes (5)
  1. Familial Mediterranean Fever Quality of Life Scale (FMF-QoL)

    FMF-QoL was developed to evaluate the quality of life in FMF patients. This scale consists of 20 questions in the form of a Likert scale and the total scoring is between 0-80. High scores indicate a decrease in quality of life.

    Measured: 6 months

  2. Hospital Anxiety and Depression Scale (HADS)

    This scale consists of 14 questions in total, and anxiety symptoms are questioned in half of the questions and depression-related complaints in the other half. A subscore of 8 or higher for depression or anxiety is considered a clinical case.

    Measured: 6 months

  3. Fibromyalgia Rapid Screening Tool (FIRST)

    This scale consists of 6 questions investigating the most relevant clinical features of fibromyalgia. The questions are answered as yes/no and 5 or more out of 6 points in total are in favor of fibromyalgia.

    Measured: 6 months

  4. The Fatigue Severity Scale (FSS)

    It consists of a total of 9 questions in which complaints related to fatigue are scored between 0 and 7, taking into account the fatigue in the last week. The mean score is obtained by dividing the total score by 9, and it is defined as <4.0 points as no fatigue, 4.0-5.0 points at the border, and >5.0 points as fatigue.

    Measured: 6 months

  5. Jenkins Sleep Evaluation Scale (JSS)

    It is a scale in which scores between 0 and 5 are made for each symptom by questioning how many days in a month 4 sleep-related symptoms are experienced considering the last 1 month. The total score is between 0-20, and as the score increases, sleep quality deteriorates.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Oct 2022
  2. Study start15 Mar 2022
  3. Primary completion31 Oct 2022 (estimated)
  4. Study completion31 Oct 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05596643
Sponsor's protocol ID
09.2021.1427
Status last verified
Oct 2022
First submitted
24 Oct 2022
Last updated
27 Oct 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Familial Mediterranean Fever and Autonomic Dysfunction, run by Marmara University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact İmran Kalkan (+90 530 340 5594, imrankalkann55@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite Autonomic Symptom Score-31 (time frame: 6 months). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in